Continuous contact-free patient monitoring can save the US healthcare system up to $15 billion annually, according to peer-reviewed paper published in Critical Care Medicine. Conducted by researchers from Harvard School of Medicine, and a new Frost & Sullivan report, Finding Top-Line Opportunities in a Bottom-Line Healthcare Market, each hospital bed monitored with EarlySense enables hospitals to achieve a cost savings of approximately $19,940.
The cited cost savings are attributed to clinical outcome improvements published by hospitals implementing EarlySense. The technology has been proven to assist clinicians in earlier detection of patient deterioration, helping to reduce patient length of stay, minimizing ICU utilization, reducing falls and pressure ulcers, and avoiding cardiac and respiratory arrests.
By extending the clinically-proven savings to all 750,000 relevant beds in the U.S. Hospital System, it is therefore estimated that the American Healthcare system could save approximately $15 billion annually. This does not include the impact that may also be realized by extending this to the thousands of patients outside of hospital setting beds.
In addition, based on this clinical data(*), it is estimated that use of EarlySense has the annual potential to help improve care within U.S. hospital systems with the following impact:
– 301,809 Patient Fall reductions
– 1,293,469 Pressure Ulcer reductions
– 17,246,250 fewer Med /Surg Days
– 2,701,913 ICU Days eliminated
– 259,556 Code Blue Events eliminated
– 207,645 Deaths avoided
“More and more hospitals, as well as Alternate Care facilities, are taking advantage of the EarlySense technology to achieve improved economics and as a tool to help save lives. The powerful peer-reviewed data, as well as practical experience gained by clinicians using our technology on hundreds of thousands of patients, is why CFCM solutions are rapidly becoming standard of care in many institutions,” said Avner Halperin, CEO of EarlySense. “We are excited to continue to offer the most advanced CFCM solutions to our customers in the U.S. and abroad, and to expand our reach to new facilities to help achieve positive patient outcomes and improved economics for the healthcare system.”
Founded in 2004, the company’s flagship product, EverOn provides FDA-approved contact-free sensing technology monitors heart rate, respiratory rate and motion by measuring key parameters with a sensor placed underneath the patient’s mattress. The EarlySense System leverages Big Data and advanced algorithms empowering the medical staff in unmonitored wards to early detect patients’ deterioration by following and analyzing the patients’ vital signs and motion. This enables the nursing staff to improve clinical outcomes and proactively reduce length of stay in the hospital’s general wards and in ICU, and also reduce adverse events such as pressure ulcers and falls
Additionally, EarlySense technology also powers several consumer health products including Samsung’s SleepSense, iFit’s Sleep Sensor and Beurer’s SE 80 Sleep Expert. The company is based in Ramat Gan, Israel with a research and development facility in Israel and marketing offices in Boston, Massachusetts.
